Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Shop vibrant dresses, standout activewear, and iconic Lilly Pulitzer prints for 60% off—only for 48 hours. Grab your Lilly Pop-Up Sale favorites now before sizes and styles start selling out fast.

In November 2023, influencer Lilly Sabri‘s picture-perfect life crumbled when she woke up to find thousands of messages from women who believed her fiancé, Alex Tyrwhitt, had cheated on her ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

The weight loss drug market could grow to $500 billion over the next decade. Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now. The GLP-1 agonist opportunity is gearing up for its next ...

Learn More » Patients self-administer, through injection, the Novo Nordisk and Lilly drugs, and they do this on a weekly basis. The pharma giants aren't stopping there, though. The next big ...

On Wednesday, pharmaceutical giant Eli Lilly sued four prominent telehealth companies that offer more affordable, off-brand versions of its patented best-selling GLP-1 medications Mounjaro and ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...